Angina Pectoris News and Research RSS Feed - Angina Pectoris News and Research

Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy reduces the risk of cardiovascular (CV) events, strokes and mortality in hypertensive older adults, according to research presented at ESC Congress 2014 today by Dr Maciej Ostrowski from Poland. [More]
Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) has announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is “highly warranted” to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery. [More]
Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. [More]
Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. [More]
Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones. [More]
Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Success rates soared to 75% for patients who waited less than 2 years for a spinal cord stimulator (SCS) implant, compared with 15% for patients whose implants happened 20 years after the onset of pain, according to a retrospective analysis. [More]
POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013. [More]
Long-term exposure to particulate matter linked with increased risk for heart attack

Long-term exposure to particulate matter linked with increased risk for heart attack

Long-term exposure to particulate matter is associated with an increased risk for heart attack. Moreover, this association can already be observed in levels of particulate exposure below the current specified European limit values. [More]
Psychotic symptoms alone denote medical health risk

Psychotic symptoms alone denote medical health risk

People with symptoms of psychosis have an increased rate of medical comorbidities and unhealthy lifestyle habits even if they do not have a psychiatric diagnosis, shows a worldwide study. [More]
High-intensity exercise protective against coronary heart disease

High-intensity exercise protective against coronary heart disease

High-intensity exercise is shown to be protective against coronary heart disease and is well known as a popular and time-saving approach to getting fit. But what about people who already have heart disease? Previously, these patients were told to exercise, but only at a moderate intensity to protect their hearts. More recently, however, researchers have found that high-intensity exercise is very beneficial for these patients. [More]
Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540. [More]
Boehringer Ingelheim, Lilly initiate linagliptin clinical trial in adults with Type 2 Diabetes

Boehringer Ingelheim, Lilly initiate linagliptin clinical trial in adults with Type 2 Diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta). [More]
Routine use of FFR at diagnostic coronary angiography changes management in 26% of patients

Routine use of FFR at diagnostic coronary angiography changes management in 26% of patients

Routinely measuring fractional flow reserve using pressure wire assessment during coronary angiography for diagnosis of chest pain leads to significant changes in the management of one in four patients, according to results from a study reported at EuroPCR 2013. [More]
Allopurinol may improve CV outcomes in kidney disease

Allopurinol may improve CV outcomes in kidney disease

The xanthine oxidase inhibitor allopurinol appears to be beneficial in preventing cardiovascular morbidity and all-cause mortality in patients with hypertensive nephropathy, show findings from a Japanese study. [More]
Intramyocardial injection of organ-derived stem cells after AMI improves left ventricle function

Intramyocardial injection of organ-derived stem cells after AMI improves left ventricle function

A study published in the current issue of Cell Transplantation, now freely available on-line, has found that when mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy. [More]
Cardiac ischemia plays an important role in adenovector gene transfection in mammalian hearts

Cardiac ischemia plays an important role in adenovector gene transfection in mammalian hearts

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA. [More]
Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide. [More]
ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States. [More]
Combination of prasugrel plus ASA can treat acute coronary syndrome

Combination of prasugrel plus ASA can treat acute coronary syndrome

In order to better prevent blood clots, the drugs clopidogrel or prasugrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid. [More]
Ivabradine effective in reducing risk of cardiac fibrosis, diastolic heart failure

Ivabradine effective in reducing risk of cardiac fibrosis, diastolic heart failure

The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure and cardiac fibrosis. [More]